Edition:
United States

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.76USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,688
52-wk High
$6.50
52-wk Low
$1.35

Select another date:

Fri, Dec 8 2017

BRIEF-Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology

* SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results

BRIEF-Soleno Therapeutics regains compliance with Nasdaq listing requirements

* Soleno Therapeutics regains compliance with nasdaq listing requirements Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics announces 1-for-5 reverse stock split

* Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics receives scientific advice from EMA

* Soleno Therapeutics says ‍has received scientific advice from CHMP of European Medicines Agency regarding diazoxide choline controlled-release for treatment of prader-willi syndrome

BRIEF-Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

* Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics issues new U.S. patent for DCCR in treatment of Prader-Willi syndrome

* Soleno Therapeutics announces issuance of new U.S. patent for DCCR in treatment of Prader-Willi syndrome

BRIEF-Soleno Therapeutics reports Q2 loss/share of $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

BRIEF-Soleno Therapeutics Q2 loss per share $0.07

* Soleno Therapeutics provides corporate update and reports second quarter 2017 financial results

BRIEF-Soleno Therapeutics announces sale of non-strategic assets to Flexicare Inc

* Soleno Therapeutics announces sale of non-strategic assets to Flexicare, Inc.

Select another date: